Skip to main content

Acute Urinary Retention

Acute urinary retention (AUR) is a urological emergency characterized by a sudden, painful inability to void. Immediate management is prompt and complete bladder decompression by catheterization.[1][2] Rapid, complete emptying is generally appropriate for AUR; routine clamping has not shown a clear benefit in the main comparative evidence. Decompression still requires monitoring in high-risk patients.[3]

Part I: Definition, epidemiology, and etiology​

Definition and classification​

AUR is defined by the International Continence Society as a painful, palpable, or percussible bladder in a patient unable to pass urine.[4] It is distinguished from chronic urinary retention (CUR), for which the AUA non-neurogenic consensus definition uses PVR >300 mL on two or more occasions persisting for ≥6 months. This is not a universal definition for acute, neurologic, traumatic or oncologic retention.[1]

  • Spontaneous AUR — no identifiable precipitant; worse prognosis and higher surgical rates (71% of the BPH-associated AUR cases in the Reten-World survey were spontaneous).[5]
  • Precipitated AUR — triggered by an identifiable event (anesthesia [28.5%], excessive alcohol [18.2%], medications, constipation, UTI); better prognosis with higher TWOC success rates.[5]

Epidemiology​

AUR predominantly affects men, with an incidence of 2.2–6.8 per 1,000 men per year, rising sharply after age 70.[2] Mortality within the year following an AUR episode is significantly higher than in the general population, particularly in younger patients — AUR is a marker of systemic disease burden, not merely a local problem.[2] A 2012 Medicare claims study found urinary-retention diagnoses in 1,532 per 100,000 female beneficiaries, with neurologic conditions, UTI and prolapse associated with retention. This measures all coded retention in an older insured population, not female AUR incidence.[6]

Etiology​

CategoryCommon causes
Obstructive (most common)BPH (53% of all AUR), urethral stricture, bladder-neck contracture, prostate cancer, phimosis, meatal stenosis, blood clots (clot retention), bladder stones
Obstructive — female-specificPelvic organ prolapse (cystocele, uterine prolapse), uterine leiomyomas (posterior / fundal with retroverted uterus), pelvic masses, urethral diverticulum
Infectious / inflammatoryAcute bacterial prostatitis, cystitis, urethritis, vulvovaginitis, herpes simplex (sacral radiculitis), periurethral abscess
PharmacologicAnticholinergics, alpha-adrenergic agonists (decongestants), opioids, benzodiazepines, NSAIDs, calcium-channel blockers, antihistamines, tricyclic antidepressants
NeurologicSpinal cord injury, cauda equina syndrome, multiple sclerosis, diabetic neuropathy, stroke, Parkinson's disease, Fowler's syndrome (young women)
PostoperativeRegional / general anesthesia, pelvic surgery, prolonged immobilization, pain / opioid use
[1][2][4][7][8][9][10]

Fowler's syndrome deserves special mention as a cause of AUR in young women (typically ages 20–30), characterized by impaired urethral sphincter relaxation, large bladder capacity, reduced sensation, and detrusor underactivity. It is associated with polycystic ovary syndrome and may respond to sacral neuromodulation in selected patients. SNM also has a role in other refractory nonobstructive retention phenotypes; published success rates depend on selection and test-phase response.[10][37]

Part II: Initial evaluation​

Principle 1 — Rapid assessment before catheterization​

While catheterization should not be delayed, a focused assessment guides the approach:[1][7]

  • History — duration of inability to void, pain severity, prior voiding symptoms (LUTS), medication review (anticholinergics, opioids, alpha-agonists, herbal supplements), prior urologic history (strictures, BPH, prior catheterization), and neurologic symptoms (saddle anesthesia, lower-extremity weakness, bowel dysfunction — red flags for cauda equina syndrome).
  • Physical examination — suprapubic palpation / percussion (distended bladder), digital rectal examination (prostate size, tenderness suggesting prostatitis, rectal tone), focused neurologic exam (perineal sensation, anal sphincter tone, lower-extremity reflexes), and pelvic exam in women (prolapse, masses).
  • Bladder scanner — the RAND / UCLA expert panel (URECA algorithm) recommends bladder scanning as the preferred diagnostic tool over catheterization for confirming retention. Its adult inpatient thresholds are ≥300 mL when symptomatic and ≥500 mL when asymptomatic, with intermittent catheterization preferred at lower volumes. These consensus thresholds are not universal definitions or reasons to defer drainage of a clinically urgent obstruction.[13]

Principle 2 — Rule out urethral injury before catheterization​

In the trauma setting, urethral catheterization must be preceded by assessment for urethral injury. The ACS Best Practices Guidelines state:[14]

  • Abort the procedure if any resistance is encountered during catheter advancement or if urine is not obtained.
  • Consider retrograde urethrography (RUG) if urethral injury is suspected (blood at the meatus, perineal hematoma, high-riding prostate, pelvic fracture).
  • A straight-tip Foley catheter is preferred in trauma; coudé-tip catheters are not recommended in this setting.

Part III: Emergent bladder decompression — techniques​

Principle 3 — Urethral catheterization: first-line approach​

Urethral catheterization is the standard first-line intervention for AUR, performed in 87–90% of cases worldwide.[2][5]

Standard technique:

  • Sterile preparation and draping; generous application of 2% lidocaine gel into the urethra (allow 5–10 minutes for anesthetic effect).
  • Catheter size — 14–16 Fr for uncomplicated adult drainage; large-bore hematuria catheter, usually ≥22 Fr, for substantial clot retention when anatomy permits.
  • Advance the catheter to the hub (in males) before inflating the balloon — premature inflation is a leading cause of iatrogenic urethral injury.[14]
  • Inflate the balloon only after urine is seen draining in the tubing.[14]
  • Secure the catheter to the thigh to prevent inadvertent traction / extraction.[14]

The coudé catheter. The coudé (curved-tip) catheter is designed to navigate the upward angulation at the prostatic urethra in men with BPH. Miller et al. reported a reduction from 18/601 (3.0%) to 4/2,038 (0.2%) after a combined nursing-education and coudé-kit program for adult male OR patients. This single-center before/after project does not isolate the catheter effect or establish universal use in trauma.[15] The tip is oriented with the curve facing anteriorly (toward the ceiling in supine patients) to glide over the prostatic obstruction.

Principle 4 — Managing difficult urethral catheterization​

When standard catheterization fails, a stepwise escalation algorithm should be followed rather than repeated blind attempts (which cause urethral trauma, false passages, and edema):[16][17]

Step 1 — Optimize the initial attempt:

  • Ensure adequate lubrication and anesthesia (lidocaine gel, 5–10 min dwell time).
  • Try a coudé-tip catheter if a straight catheter fails.
  • Stretch the penis to its full length and hold it perpendicular to the body to straighten the urethra.

Step 2 — Seek experienced assistance and define the obstruction:

  • Suspected stricture, false passage or prior urethral surgery favors early flexible cystoscopy rather than repeated blind instrumentation.
  • Under direct vision, pass a guidewire into the bladder, then advance an appropriate Council-tip catheter over it.
  • Beaghler et al. reported placement in 52/54 patients in a prospective series; this is a cohort result, not a guaranteed success rate.[17]

Step 3 — Selected guidewire/device approaches:

  • Hydrophilic-wire and integrated devices have been described by experienced operators, including the UCD.[18] They are not a mandatory blind step before cystoscopy. Confirm intravesical wire position; do not force wire or catheter passage.

Step 4 — Fluoroscopy-guided catheterization:

  • For cases where cystoscopy fails or is unavailable, Kim et al. demonstrated 100% technical and clinical success in 179 procedures in 149 men in a retrospective cohort, with a 2.2% procedure-related complication rate.[19]

Step 5 — Suprapubic catheterization (see below).

Principle 5 — Suprapubic catheterization: when urethral access fails or is contraindicated​

Suprapubic catheter (SPC) placement is indicated when urethral catheterization fails, is contraindicated, or is not feasible:[20][21][22]

Indications:

  • Failed urethral catheterization after stepwise escalation.
  • Known urethral disruption (trauma) or complete urethral stricture.
  • Acute bacterial prostatitis (relative — to avoid urethral manipulation through an infected gland).[9]
  • When long-term indwelling drainage is needed, SPC may offer comfort, sexual-function or urethral-protection advantages. The short-term Cochrane bacteriuria findings do not establish lower long-term symptomatic UTI rates.[23][24]

Contraindications and precautions:

  • A bladder that cannot be adequately distended and safely localized is unsuitable for blind percutaneous insertion.
  • Known/suspected bladder cancer and gross hematuria require specialist assessment; EAUN lists these as contraindications to routine SPC insertion.
  • Prior lower-abdominal surgery, pregnancy, anticoagulation/coagulopathy and intervening abdominal-wall infection require individualized access planning; prior surgery is not an absolute ban on all SPC routes.[20][24][35]

Technique — percutaneous (bedside):

  • Confirm bladder distension by palpation and ultrasound — Aguilera et al. demonstrated 100% success with real-time ultrasound-guided SPC placement in 17 ED patients with zero complications.[22]
  • Entry point: 3 cm above the pubic symphysis in the midline (or 1–2 cm off midline).
  • Choose the entry site and trajectory under imaging according to the visualized bladder and intervening structures; avoid an assumed blind trajectory.
  • Goyal et al. reported successful bedside trocar SPC placement in 72 consecutive patients with no complications, with average procedure time <5 minutes.[21]
  • Bowel-injury risk — 0–2.7%; the primary concern, particularly in patients with prior abdominal surgery or an inadequately distended bladder.[9]

Technique — open cystostomy:

  • Reserved for patients with prior pelvic surgery where peritoneal adhesions may overlie the bladder, making percutaneous access dangerous.
  • A small infraumbilical midline or transverse incision is made, the rectus muscles are separated, the peritoneum is displaced cephalad, and the bladder is opened between stay sutures.
  • A Malecot or Foley catheter is placed through the bladder wall and secured in a long oblique tunnel away from the symphysis.

Suprapubic vs. urethral catheterization: the Cochrane review (Kidd et al.) found SPCs associated with less pain, lower rates of asymptomatic bacteriuria, and fewer recatheterizations than indwelling urethral catheters for short-term use.[24] However, insertion complications (bowel injury, catheter malpositioning) are underreported in trials, and the intraoperative complication rate in one NHS audit was 10%.[24]

Part IV: Rapid vs. gradual decompression — the evidence​

Principle 6 — Rapid, complete emptying is recommended​

The 1997 Nyman review predates randomized evidence.[3] A 294-patient randomized trial subsequently found no significant difference in hematuria (11.3% gradual versus 10.5% rapid) and no circulatory collapse.[32] A 2022 meta-analysis of four studies (435 participants) likewise found no clear increase in hematuria with rapid drainage (RR 0.91, 95% CI 0.62–1.35).[33]

Evidence is less uniform in chronic retention: a small 2024 randomized study of 60 men with CUR reported more gross hematuria after rapid drainage, with sparse transfusion events and no significant transfusion difference. This does not establish routine clamping for AUR, but rules out claims that no trials or conflicting data exist.[34]

The potential complications of decompression — hematuria, hypotension, and postobstructive diuresis — can follow decompression; most are self-limited, but substantial bleeding, hypovolemia and pathologic diuresis can be serious:[3]

ComplicationIncidenceSignificanceManagement
Hematuria (ex vacuo)2–16%Rarely clinically significant; decompression of overdistended mucosal vesselsUsually self-limited; continuous bladder irrigation if persistent; rarely requires intervention
HypotensionCommon (transient BP drop)Usually normalizes spontaneously; rarely progresses to clinically significant hypotensionIV fluid bolus if symptomatic; monitor elderly and hypovolemic patients closely
Postobstructive diuresis (POD)0.5–52%Usually physiologic and self-limited (<24 h); pathologic POD (>48 h) is rare but potentially lethalSee Part V below

Part V: Postobstructive diuresis — recognition and management​

Principle 7 — Physiologic vs. pathologic POD​

Postobstructive diuresis is defined as urine output ≥200 mL/hour for 2 consecutive hours or >3 L over 24 hours following relief of urinary obstruction.[25][26]

Physiologic POD — self-limited, <48 hours, self-resolving.

  • Represents the normal diuretic response to resolution of fluid overload and retained solute load.

Pathologic POD — >48 hours, potentially life-threatening.

  • Results from intrinsic tubular damage caused by prolonged obstruction.
  • Pathophysiology:[25][27][28]
    • Medullary washout — loss of the corticomedullary concentration gradient.
    • Downregulation of sodium transporters in the thick ascending limb of Henle.
    • Resistance to ADH (nephrogenic diabetes insipidus-like state).
    • Osmotic diuresis from retained urea.
    • Natriuresis from impaired tubular sodium reabsorption.
  • Can lead to severe dehydration, electrolyte derangements (hyponatremia, hypokalemia, hypomagnesemia), hypotension, and shock if not recognized and treated.[25][26]

Risk factors for pathologic POD:

  • Bilateral ureteral obstruction or obstruction of a solitary kidney.
  • Chronic retention with renal insufficiency (elevated BUN / creatinine).
  • Volume overload, CHF, or edematous states.
  • Prolonged duration of obstruction.[26]

Principle 8 — Management of POD​

  • Monitor urine output hourly for the first 24–48 hours after decompression in high-risk patients (chronic retention, elevated creatinine, bilateral obstruction).
  • Replace fluids according to volume status and serial electrolytes. In initially volume-overloaded patients, replacement of approximately 50–75% of recent urine output is a starting approach, with oral intake when feasible. Fluid composition and rate must be individualized; hypovolemia or shock requires appropriate resuscitation, and 0.45% saline is not a universal choice.[26][27]
  • Monitor electrolytes (Na, K, Mg, phosphate) every 6–12 hours during active diuresis.
  • Avoid overzealous fluid replacement — the most common iatrogenic error; converts physiologic POD into pathologic POD.[27]
  • Taper IV fluids as urine output decreases; transition to oral intake as tolerated.
  • Nephrology consultation for pathologic POD lasting >48 hours or associated with hemodynamic instability.[25]

Part VI: Post-decompression management — trial without catheter (TWOC)​

Principle 9 — Alpha-blocker therapy before TWOC​

The Cochrane review rated its pooled evidence moderate quality, while the later EAU-panel review rated the agent-specific comparisons low certainty; both found that alpha-1 blockers increase TWOC success rates in men with presumed benign prostatic obstruction:[29][30]

  • Alfuzosin — TWOC success 60% vs. 39% placebo (OR 2.28, 95% CI 1.55–3.36; 7 RCTs, 940 patients).[29]
  • Tamsulosin — TWOC success 47% vs. 29% placebo (OR 2.40, 95% CI 1.29–4.45; 3 RCTs, 297 patients).[29]
  • Alpha-blockers doubled the odds of successful TWOC in the Reten-World survey (OR 1.92, 95% CI 1.52–2.42).[5]
  • Head-to-head alfuzosin versus tamsulosin evidence is very low certainty and does not establish equivalence.[29]
  • Reported adverse-event rates were low, but trial evidence was limited; assess dizziness, hypotension and falls risk.[30]

Principle 10 — Timing and conduct of TWOC​

  • Individualize TWOC timing to the cause, stabilization, catheter-related injury and alpha-blocker exposure. Reten-World used a median of five days, not three.[5]
  • In that observational survey, catheterization >3 days was associated with greater morbidity without higher TWOC success; this does not prove that every patient should undergo removal within three days.
  • Overall TWOC success rate — 23–61% depending on population and alpha-blocker use.[2][31][5]
  • Predictors of TWOC failure — age ≥70, prostate ≥50 g, severe LUTS, drained volume ≥1,000 mL, spontaneous (vs. precipitated) AUR.[5]
  • After failed TWOC — 49% undergo BPH surgery; 43.5% attempt a second TWOC (success rate 29.5%).[5]

Principle 11 — Surgical management after failed TWOC​

Emergency surgery (within days of AUR) carries greater morbidity and mortality than elective surgery and is discouraged.[2][23] Current practice favors:

  • Elective outlet surgery — select TURP, enucleation or another appropriate procedure according to prostate anatomy, comorbidity, goals and expertise.[23]
  • Laser enucleation (HoLEP, ThuLEP) — established options; detailed selection is covered in the BPH treatment atlas.[23]
  • Clean intermittent self-catheterization (CISC) — a safe bridge to definitive surgery, particularly in patients with significant comorbidities precluding immediate surgery.[23]

Part VII: Special populations​

Clot retention​

Clot retention is a specific form of AUR caused by blood clots obstructing the bladder outlet or catheter. Management requires:

  • Large-bore hematuria catheter, usually ≥22 Fr; a 3-way catheter supports subsequent irrigation to facilitate manual irrigation and clot evacuation.
  • Continuous bladder irrigation with normal saline after clot evacuation.
  • If manual irrigation fails, cystoscopy with clot evacuation and fulguration of bleeding sources.
  • Identify and treat the underlying cause (bladder tumor, radiation cystitis, anticoagulation).

Acute bacterial prostatitis with retention​

Drain clinically significant retention. The URECA 300/500-mL thresholds describe general adult inpatients, not a validated prostatitis-specific rule.[9] Urethral catheterization is typically more practical than SPC, though SPC avoids manipulation through the infected gland.[9]

Neurogenic bladder​

Patients with AUR from neurologic causes (spinal cord injury, MS, cauda equina) require treatment of the cause and risk-based follow-up. Intermittent catheterization is preferred when ongoing assisted emptying is needed and feasible, rather than mandated indefinitely for every episode.[1] Acute prolonged bladder overdistension from undetected retention (e.g., after regional anesthesia or prolonged labor) can cause irreversible detrusor damage — vigilant monitoring is paramount.[12]

Women with AUR​

AUR in women is uncommon and warrants thorough evaluation for:[4][7][8][10][11]

  • Pelvic organ prolapse (most common obstructive cause).
  • Uterine leiomyomas — especially posterior / fundal with retroverted uterus; can compress the urethra or pelvic plexus.[8]
  • Fowler's syndrome (young women with impaired urethral relaxation).[10]
  • Neurologic causes (most common in reproductive-age women).[4]
  • Psychological comorbidities and functional neurologic disorders (increasingly recognized).[11]

Part VIII: Catheter selection and infection prevention​

Catheter typeAdvantagesDisadvantagesBest indication
Urethral indwelling (Foley)Widely available; requires trained insertion and safe balloon positioningUTI risk increases with duration; urethral trauma; patient discomfortShort-term AUR management; perioperative use
Suprapubic catheterLess pain; lower bacteriuria; easier hygiene; no urethral traumaRequires trained placement; bowel-injury risk (0–2.7%); requires distended bladderFailed urethral catheterization; long-term catheterization; urethral injury
Clean intermittent catheterizationPatient autonomy; avoids a continuously indwelling catheter; infection risk depends on settingRequires dexterity and training; multiple daily insertionsNeurogenic bladder; bridge to surgery; chronic retention
Coudé-tip catheterNavigates prostatic urethra; reduced traumatic catheterization from 3.0% to 0.2%Requires proper orientation techniqueSelected difficult male catheterization or BPH; local trained protocol

Infection prevention:

  • Silver alloy-coated and antibiotic-impregnated catheters offer clinically insignificant or no benefit and are not routinely recommended.[1]
  • The single most important intervention is minimizing catheter dwell time — remove as soon as clinically indicated.[20]
  • Bacteriuria, not symptomatic CAUTI, develops at approximately 3–7% per catheter day. Asymptomatic bacteriuria usually does not require antibiotics.[36]

Summary — stepwise approach to AUR and emergent decompression​

  1. Confirm retention — assess symptoms and scan; URECA 300/500-mL cutoffs apply to adult inpatient scenarios, not every emergency.[13]
  2. Rule out urethral injury in trauma — blood at meatus → RUG before catheterization.[14]
  3. Urethral catheterization — sterile technique, lidocaine gel, 14–16 Fr (coudé in males with BPH); inflate balloon only after urine drains.[15][14]
  4. Rapid, complete decompression — no clamping; drain the bladder fully.[3]
  5. Monitor for POD — hourly urine output for 24–48 hours in high-risk patients; replace 50–75% of output; monitor electrolytes.[26]
  6. Start an alpha-blocker for presumed BPH-related AUR, if suitable; this does not apply to every cause of retention.[29][30]
  7. Plan TWOC after stabilization and appropriate alpha-blocker exposure — individualize timing and assess voiding.[2][5]
  8. If TWOC fails — recatheterize → elective surgery (TURP / laser) or second TWOC attempt.[5]
  9. If urethral catheterization fails — escalate stepwise (trained coudé attempt when appropriate → visualized guidewire/cystoscopy or image-guided access → suprapubic drainage when needed).[16][17]

See Also​

References​

1. Serlin DC, Heidelbaugh JJ, Stoffel JT. "Urinary retention in adults: evaluation and initial management." Am Fam Physician. 2018;98(8):496–503.

2. Emberton M, Fitzpatrick JM. "The Reten-World survey of the management of acute urinary retention: preliminary results." BJU Int. 2008;101(Suppl 3):27–32. doi:10.1111/j.1464-410X.2008.07491.x

3. Nyman MA, Schwenk NM, Silverstein MD. "Management of urinary retention: rapid versus gradual decompression and risk of complications." Mayo Clin Proc. 1997;72(10):951–956. doi:10.1016/S0025-6196(11)63368-5

4. Andrada AO, De Vicente JM, Cidre MA. "Pelvic plexus compression due to a uterine leiomyoma in a woman with acute urinary retention: a new hypothesis." Int Urogynecol J. 2014;25(3):429–431. doi:10.1007/s00192-013-2158-z

5. Fitzpatrick JM, Desgrandchamps F, Adjali K, et al. "Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasia." BJU Int. 2012;109(1):88–95. doi:10.1111/j.1464-410X.2011.10430.x

6. Cohn JA, Ni S, Kaufman MR, et al. "Urinary retention and catheter use among U.S. female Medicare beneficiaries: prevalence and risk factors." Neurourol Urodyn. 2017;36(8):2101–2108. doi:10.1002/nau.23248

7. Selius BA, Subedi R. "Urinary retention in adults: diagnosis and initial management." Am Fam Physician. 2008;77(5):643–650.

8. Wu CQ, Lefebvre G, Frecker H, Husslein H. "Urinary retention and uterine leiomyomas: a case series and systematic review of the literature." Int Urogynecol J. 2015;26(9):1277–1284. doi:10.1007/s00192-015-2665-1

9. Borgert BJ, Wallen EM, Pham MN. "Prostatitis." JAMA. 2025;334(11):1003–1013. doi:10.1001/jama.2025.11499

10. Szymański JK, Słabuszewska-Jóźwiak A, Jakiel G. "Fowler's syndrome — the cause of urinary retention in young women, often forgotten, but significant and challenging to treat." Int J Environ Res Public Health. 2021;18(6):3310. doi:10.3390/ijerph18063310

11. Panicker JN, Anding R, Arlandis S, et al. "Do we understand voiding dysfunction in women? Current understanding and future perspectives: ICI-RS 2017." Neurourol Urodyn. 2018;37(S4):S75–S85. doi:10.1002/nau.23709

12. Madersbacher H, Cardozo L, Chapple C, et al. "What are the causes and consequences of bladder overdistension? ICI-RS 2011." Neurourol Urodyn. 2012;31(3):317–321. doi:10.1002/nau.22224

13. Chrouser K, Fowler KE, Mann JD, et al. "Urinary retention evaluation and catheterization algorithm for adult inpatients." JAMA Netw Open. 2024;7(7):e2422281. doi:10.1001/jamanetworkopen.2024.22281

14. Johnsen N, Wessells H, Archer-Arroyo K, et al. Best Practices Guidelines: Management of Genitourinary Injuries. American College of Surgeons; 2025.

15. Miller D, Pelzman D, Bonfili J, et al. "Implementation of a standardized process of coudé catheter insertion decreases traumatic catheterizations." Urology. 2024;194:253–259. doi:10.1016/j.urology.2024.10.016

16. Willette PA, Coffield S. "Current trends in the management of difficult urinary catheterizations." West J Emerg Med. 2012;13(6):472–478. doi:10.5811/westjem.2011.11.6810

17. Beaghler M, Grasso M, Loisides P. "Inability to pass a urethral catheter: the bedside role of the flexible cystoscope." Urology. 1994;44(2):268–270. doi:10.1016/s0090-4295(94)80148-7

18. Bugeja S, Mistry K, Yim IHW, et al. "A new urethral catheterisation device (UCD) to manage difficult urethral catheterisation." World J Urol. 2019;37(4):595–600. doi:10.1007/s00345-018-2499-9

19. Kim SW, Nam IC, Kim DR, et al. "Safety and efficacy of fluoroscopy-guided urethral catheterization in case of failed blind or cystoscopy-assisted urethral catheterization." Sci Rep. 2024;14(1):9406. doi:10.1038/s41598-024-60224-1

20. Fletke KJ, Jeong DH, Herrera AV. "Urinary catheter management." Am Fam Physician. 2024;110(3):251–258.

21. Goyal NK, Goel A, Sankhwar SN. "Safe percutaneous suprapubic catheterisation." Ann R Coll Surg Engl. 2012;94(8):597–600. doi:10.1308/003588412X13373405385412

22. Aguilera PA, Choi T, Durham BA. "Ultrasound-guided suprapubic cystostomy catheter placement in the emergency department." J Emerg Med. 2004;26(3):319–321. doi:10.1016/j.jemermed.2003.11.016

23. Yoon PD, Chalasani V, Woo HH. "Systematic review and meta-analysis on management of acute urinary retention." Prostate Cancer Prostatic Dis. 2015;18(4):297–302. doi:10.1038/pcan.2015.15

24. Kidd EA, Stewart F, Kassis NC, Hom E, Omar MI. "Urethral (indwelling or intermittent) or suprapubic routes for short-term catheterisation in hospitalised adults." Cochrane Database Syst Rev. 2015;(12):CD004203. doi:10.1002/14651858.CD004203.pub3

25. Finger E, Moses A. "As the river flows: a case report of post-obstructive diuresis." BMC Nephrol. 2025;26(1):341. doi:10.1186/s12882-025-04215-y

26. Halbgewachs C, Domes T. "Postobstructive diuresis: pay close attention to urinary retention." Can Fam Physician. 2015;61(2):137–142.

27. Peterson LJ, Yarger WE, Schocken DD, Glenn JF. "Post-obstructive diuresis: a varied syndrome." J Urol. 1975;113(2):190–194. doi:10.1016/s0022-5347(17)59440-9

28. Baum N, Anhalt M, Carlton CE, Scott R. "Post-obstructive diuresis." J Urol. 1975;114(1):53–56. doi:10.1016/s0022-5347(17)66942-8

29. Karavitakis M, Kyriazis I, Omar MI, et al. "Management of urinary retention in patients with benign prostatic obstruction: a systematic review and meta-analysis." Eur Urol. 2019;75(5):788–798. doi:10.1016/j.eururo.2019.01.046

30. Fisher E, Subramonian K, Omar MI. "The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men." Cochrane Database Syst Rev. 2014;(6):CD006744. doi:10.1002/14651858.CD006744.pub3

31. Fitzpatrick JM, Kirby RS. "Management of acute urinary retention." BJU Int. 2006;97(Suppl 2):16–22. doi:10.1111/j.1464-410X.2006.06100.x

32. Boettcher S, Brandt AS, Roth S, Mathers MJ, Lazica DA. Urinary retention: benefit of gradual bladder decompression—myth or truth? A randomized controlled trial. Urol Int. 2013;91:140–144. doi:10.1159/000350943.

33. Wu MY, Chang JR, Lee YK, et al. The Effect and Safety of Rapid and Gradual Urinary Decompression in Urine Retention: A Systematic Review and Meta-Analysis. Medicina. 2022;58(10):1441. PubMed.

34. Odeyemi PO, Idowu NA. Comparison of post-decompressive haematuria in rapid versus gradual bladder decompression in patients with chronic urinary retention. J West Afr Coll Surg. 2024;14(3):249–254. doi:10.4103/jwas.jwas_5_24.

35. European Association of Urology Nurses. Indwelling catheterisation in adults—urethral and suprapubic. 2024. Indications and contraindications.

36. Centers for Disease Control and Prevention. Indwelling urinary catheter culture stewardship: overview. Guidance.

37. European Association of Urology. Non-neurogenic Female LUTS Guidelines: underactive bladder and functional obstruction. 2026. Guideline.